{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:46:46Z","timestamp":1763038006852,"version":"3.37.3"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["19\/242"],"award-info":[{"award-number":["19\/242"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejphar.2024.176844","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T23:40:48Z","timestamp":1721778048000},"page":"176844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The impact of piperazine and antipsychotic co-exposures and CB1 blockade on the effects elicited by AMB-FUBINACA, a synthetic cannabinoid, in mice"],"prefix":"10.1016","volume":"979","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-5956","authenticated-orcid":false,"given":"Lucy R.","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-6898","authenticated-orcid":false,"given":"Michelle","family":"Glass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-0719","authenticated-orcid":false,"given":"Rhonda J.","family":"Rosengren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejphar.2024.176844_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/15563650.2019.1580371","article-title":"Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA","volume":"57","author":"Adamowicz","year":"2019","journal-title":"Clinical toxicology (Philadelphia, Pa.)"},{"issue":"5 Suppl. 2","key":"10.1016\/j.ejphar.2024.176844_bib2","first-page":"S68","article-title":"Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations","volume":"53","author":"Alldredge","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ejphar.2024.176844_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biopsych.2006.09.023","article-title":"Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports","volume":"62","author":"Alper","year":"2007","journal-title":"Biol. Psychiatr."},{"issue":"7","key":"10.1016\/j.ejphar.2024.176844_bib4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1211\/jpp\/61.07.0006","article-title":"Metabolic interactions with piperazine-based 'party pill' drugs","volume":"61","author":"Antia","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176844_bib5","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3533","article-title":"Induction of temporal lobe epilepsy in mice with pilocarpine","volume":"10","author":"Arshad","year":"2020","journal-title":"Bio-protocol"},{"issue":"9","key":"10.1016\/j.ejphar.2024.176844_bib6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.6b00137","article-title":"Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues","volume":"7","author":"Banister","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176844_bib7","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1476-5381.1991.tb12342.x","article-title":"Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia","volume":"103","author":"Bill","year":"1991","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176844_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1528-1167.2008.01710.x","article-title":"Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis","volume":"50","author":"Blumenfeld","year":"2009","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.ejphar.2024.176844_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/molecules26051396","article-title":"A systematic study of the in vitro pharmacokinetics and estimated human in vivo clearance of indole and indazole-3-carboxamide synthetic cannabinoid receptor agonists detected on the illicit drug market","volume":"26","author":"Brandon","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2024.176844_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2014.01.062","article-title":"Risperidone inhibits voltage-gated sodium channels","volume":"728","author":"Brauner","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2601","article-title":"Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies","volume":"32","author":"Canazza","year":"2017","journal-title":"Hum. Psychopharmacol."},{"issue":"13","key":"10.1016\/j.ejphar.2024.176844_bib12","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.2174\/13816128113199990430","article-title":"Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones","volume":"20","author":"Castelli","year":"2014","journal-title":"Curr. Pharmaceut. Des."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176844_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1441-2772(23)02118-X","article-title":"Induced and accidental hypothermia","volume":"2","author":"Connolly","year":"2000","journal-title":"Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine"},{"issue":"9","key":"10.1016\/j.ejphar.2024.176844_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/02698811231182012","article-title":"The New Zealand drug harms ranking study: a multi-criteria decision analysis","volume":"37","author":"Crossin","year":"2023","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176844_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s42003-022-03113-5","article-title":"In-depth comparison of the metabolic and pharmacokinetic behaviour of the structurally related synthetic cannabinoids AMB-FUBINACA and AMB-CHMICA in rats","volume":"5","author":"Fabregat-Safont","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejphar.2024.176844_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173530","article-title":"The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism","volume":"223","author":"Finlay","year":"2023","journal-title":"Pharmacology, biochemistry, and behavior"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176844_bib17","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/acschemneuro.9b00429","article-title":"Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA","volume":"10","author":"Finlay","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176844_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1476-5381.1982.tb08802.x","article-title":"Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol","volume":"75","author":"Fitton","year":"1982","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176844_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/jpet.117.246983","article-title":"Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA","volume":"365","author":"Gamage","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176844_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuro.2018.11.004","article-title":"Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids","volume":"70","author":"Gatch","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejphar.2024.176844_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fpsyt.2020.00464","article-title":"Post-mortem toxicology: a systematic review of death cases involving synthetic cannabinoid receptor agonists","volume":"11","author":"Giorgetti","year":"2020","journal-title":"Front. Psychiatr."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176844_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/1044546041649075","article-title":"No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series","volume":"14","author":"Gonzalez-Heydrich","year":"2004","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2024.176844_bib23","article-title":"A rare case of risperidone-induced hypothermia and thrombocytopenia","volume":"14","author":"Goyal","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ejphar.2024.176844_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/08897077.2013.846288","article-title":"A survey of synthetic cannabinoid consumption by current cannabis users","volume":"35","author":"Gunderson","year":"2014","journal-title":"Subst. Abuse"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4103\/ejcdt.ejcdt_191_19","article-title":"Troponin T level in children with acute chest diseases and respiratory distress","volume":"69","author":"Hegazy","year":"2020","journal-title":"Egypt. J. Chest Dis. Tuberc."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1017\/S1461145705005651","article-title":"Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment","volume":"9","author":"Hill","year":"2006","journal-title":"The international journal of neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2024.176844_bib28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fphar.2018.01084","article-title":"Atypical pharmacodynamic properties and metabolic profile of the abused synthetic cannabinoid AB-PINACA: potential contribution to pronounced adverse effects relative to \u03b49-THC","volume":"9","author":"Hutchison","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176844_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2019.110107","article-title":"The phenomenon of para-Fluorophenylpiperazine (pFPP) in combination with the synthetic cannabinoid AMB-FUBINACA in seized plant material in New Zealand","volume":"307","author":"Johnson","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.ejphar.2024.176844_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0028-3908(82)90157-5","article-title":"The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain","volume":"21","author":"Keane","year":"1982","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176844_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11419-018-0430-0","article-title":"Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures","volume":"37","author":"Kevin","year":"2019","journal-title":"Forensic Toxicol."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176844_bib32","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(97)01160-6","article-title":"SR141716A is an inverse agonist at the human cannabinoid CB1 receptor","volume":"334","author":"Landsman","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176844_bib33","article-title":"Vaping synthetic cannabinoids: a novel preclinical model of E-cigarette use in mice","volume":"11","author":"Lefever","year":"2017","journal-title":"Subst. Abuse Res. Treat."},{"issue":"43","key":"10.1016\/j.ejphar.2024.176844_bib34","doi-asserted-by":"crossref","first-page":"73613","DOI":"10.18632\/oncotarget.20280","article-title":"5-HT1a activation in PO\/AH area induces therapeutic hypothermia in a rat model of intracerebral hemorrhage","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2024.176844_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pbb.2014.05.010","article-title":"In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid \u03949-THC in mice: inhalation versus intraperitoneal injection","volume":"124","author":"Marshell","year":"2014","journal-title":"Pharmacology, biochemistry, and behavior"},{"issue":"5","key":"10.1016\/j.ejphar.2024.176844_bib36","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1471-4159.2007.04961.x","article-title":"CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A\/C receptors","volume":"103","author":"Mato","year":"2007","journal-title":"J. Neurochem."},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2024.176844_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2007.04.054","article-title":"Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL\/6J mice","volume":"569","author":"McMahon","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176844_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100460","article-title":"An outbreak of deaths associated with AMB-FUBINACA in Auckland NZ","volume":"25","author":"Morrow","year":"2020","journal-title":"EClinicalMedicine"},{"journal-title":"Report submitted to the Ministry of Health","article-title":"Insights into the synthetic cannabinoid crisis","year":"2018","key":"10.1016\/j.ejphar.2024.176844_bib39"},{"issue":"8","key":"10.1016\/j.ejphar.2024.176844_bib41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.biopsych.2011.11.027","article-title":"\u03b2-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner","volume":"71","author":"Nguyen","year":"2012","journal-title":"Biol. Psychiatr."},{"issue":"10","key":"10.1016\/j.ejphar.2024.176844_bib42","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1073\/pnas.0813330106","article-title":"Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy","volume":"106","author":"Oakley","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12940","article-title":"Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca","volume":"26","author":"Oliveira da Cruz","year":"2021","journal-title":"Addiction Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176844_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1440-1681.2005.04184.x","article-title":"Resistance to excessive bodyweight gain in risperidone-injected rats","volume":"32","author":"Ota","year":"2005","journal-title":"Clinical and experimental pharmacology & physiology"},{"key":"10.1016\/j.ejphar.2024.176844_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113871","article-title":"Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists","volume":"175","author":"Patel","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.ejphar.2024.176844_bib46","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1111\/bph.13973","article-title":"Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice","volume":"174","author":"Pryce","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation. II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib48","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1124\/jpet.301.3.963","article-title":"CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia","volume":"301","author":"Rawls","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib67","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2024.176844_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7257489","article-title":"First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone","volume":"2016","author":"Roberto","year":"2016","journal-title":"Case reports in psychiatry"},{"key":"10.1016\/j.ejphar.2024.176844_bib50","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jama.1963.63700080011017c","article-title":"Study of a narcotic antagonist--N-allyl-noroxymorphone","volume":"183","author":"Sadove","year":"1963","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176844_bib51","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0278-5846(88)90093-0","article-title":"Molecular pharmacology of niaprazine","volume":"12","author":"Scherman","year":"1988","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2024.176844_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176844_bib53","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.neuro.2008.07.005","article-title":"Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats","volume":"29","author":"Shioda","year":"2008","journal-title":"Neurotoxicology"},{"issue":"4","key":"10.1016\/j.ejphar.2024.176844_bib54","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/00365516509077065","article-title":"Plasma creatinine determination. A new and specific Jaffe reaction method","volume":"17","author":"Slot","year":"1965","journal-title":"Scandinavian journal of clinical and laboratory investigation"},{"key":"10.1016\/j.ejphar.2024.176844_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2016.03.007","article-title":"The users of Novel Psychoactive Substances: online survey about their characteristics, attitudes and motivations","volume":"32","author":"Soussan","year":"2016","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.ejphar.2024.176844_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108179","article-title":"The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice","volume":"214","author":"Trexler","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejphar.2024.176844_bib57","article-title":"UNODC early warning advisory on new psychoactive substances","volume":"1","year":"2019","journal-title":"Current NPS Threats"},{"journal-title":"Retrieved from","article-title":"Early warning advisory on new psychoactive substances - summary dashboard","year":"2024","key":"10.1016\/j.ejphar.2024.176844_bib58"},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2024.176844_bib59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.drugalcdep.2011.07.011","article-title":"A survey study to characterize use of Spice products (synthetic cannabinoids)","volume":"120","author":"Vandrey","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejphar.2024.176844_bib60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.yebeh.2019.02.029","article-title":"PTZ-induced seizures in mice require a revised Racine scale","volume":"95","author":"Van Erum","year":"2019","journal-title":"Epilepsy Behav. : E&B"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176844_bib61","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-007-0294-4","article-title":"Hypothermia following antipsychotic drug use","volume":"63","author":"van Marum","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176844_bib62","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ajhg.2012.01.006","article-title":"De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP","volume":"90","author":"Veeramah","year":"2012","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176844_bib63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11419-022-00649-3","article-title":"Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite","volume":"41","author":"Webb","year":"2023","journal-title":"Forensic Toxicol."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176844_bib64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00003246-199602000-00004","article-title":"Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients","volume":"24","author":"Weinbroum","year":"1996","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejphar.2024.176844_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2019.04.002","article-title":"Do you feel it now? Route of administration and \u03949-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice","volume":"73","author":"Wiley","year":"2019","journal-title":"Neurotoxicology"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176844_bib66","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1007\/s00213-022-06205-6","article-title":"Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice","volume":"239","author":"Wilson","year":"2022","journal-title":"Psychopharmacology"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924005338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924005338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T20:50:17Z","timestamp":1723668617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924005338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":66,"alternative-id":["S0014299924005338"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176844","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of piperazine and antipsychotic co-exposures and CB1 blockade on the effects elicited by AMB-FUBINACA, a synthetic cannabinoid, in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"176844"}}